100 Abbott Park Rd
Abbott Park, Illinois 60064-3500
Phone: 12246676100
www.abbott.com
Seasoned investors typically pay close attention to “stocks with analyst approval,” a sign of potential success and resilience in the ever-volatile equity market landscape. Currently, we are in a period of rapid technological advancements in artificial intelligence (AI) and shifting economic paradigms amid expected interest rate cuts. Thus, the importance of relying on expert equity analysis has become even more pronounced on Wall Street. Stocks have been on a tear so far in 2024, with both the S&P 500 and Nasdaq 100 indices currently sitting on year-to-date (YTD) returns of around 9%. Over the past year, the spotlight has been on well-known equity giants, especially the Magnificent 7 stocks. Yet, Wall Street offers a large pool of gems across diverse industries that can transform equity portfolios. Therefore, today’s article introduces three stocks with analyst approval that deserve our attention in April. Abbott Laboratories (ABT) The first on our list of stocks with analyst approval is the healthcare giant Abbott Laboratories (NYSE: ABT ).
Inflation came in much hotter than expected in February. Core services inflation, which excludes housing, rose 0.5% from January following a 0.9% increase from December. Last month’s gain was twice as fast as it was pre-pandemic, causing the Federal Reserve to rethink interest cutting rate too soon. Consumer spending is weakening as real disposable income fell in January. At the same time, household debt hit an unsustainable $17.5 trillion. Credit card and auto loan debt is also at record levels and rising, even as personal savings remain weak. In short, individual finances are a disaster, and the likelihood of a recession sometime this year is high. Now is the time to steel your portfolio against what is to come. The following three companies are stocks to buy for a recession, as they offer resiliency and downside protection. Walmart (WMT) In an economic crisis, consumers will shop where they can find everyday low prices. That means retail king Walmart (NYSE: WMT ) will shine. Since going public in 1970, the retailer has been through seven recessions and come out stronger each time.
As the world economy teeters on the verge of instability, three titans have survived many financial storms and emerged stronger than ever from the waves of uncertainty. Here, recognizing these business titans’ strategic acumen reveals a means to protect riches. Every firm has a different story of perseverance, but all are united by a persistent dedication to maximizing shareholder value in the face of hardship. With its strategy focusing on sales growth, margin expansion and operational efficiency, the first one is the prototypical retail giant. The company is a plinth of stability, offering investors a safe haven despite choppy market conditions. Despite the sporadic storm of non-cash impairment charges, the second one, a mainstay in the consumer products industry, regularly delivers outstanding core earnings per share growth and exhibits extraordinary adaptability in the face of adversity. In the meantime, the third one, a leader in healthcare innovation, forges on with resilience, registering double-digit organic sales growth despite the COVID-19 pandemic’s obstacles.
No summary available.
Takeover of baby formula maker Mead Johnson Nutrition could lead to billions in damages payouts The worst acquisition by a major UK company in the last decade? It’s hard to think of a deal that beats Reckitt Benckiser’s $18bn purchase in 2017 of Mead Johnson Nutrition , a US-listed maker of baby milk formula. Shares in the Dettol-to-Durex group have never recovered from the shock. By way of add-on award, Rakesh Kapoor, Reckitt’s chief executive back in the day, can probably scoop the prize for most overpaid FTSE 100 boss of recent times: he departed two years after his fateful piece of deal-making having been paid the astonishing sum of £97.6m during his eight years in charge. The latest example of Mead Johnson’s dreadful legacy was Friday’s news that a court in Illinois awarded $60m in damages to a woman whose premature baby died in intensive care after consuming the company’s Enfamil formula; the allegation was that Reckitt failed to warn adequately that feeding with infant formula increased the risk of necrotising enterocolitis (NEC).
An Illinois jury has issued a verdict compelling Reckitt Benckiser Group Plc’s (OTC: RBGLY ) (OTC: RBGPF ) Mead Johnson to pay $60 million to the mother of a premature infant who tragically succumbed to necrotizing enterocolitis (NEC) after being fed the company’s Enfamil baby formula. The jury found Mead Johnson negligent for failing to warn of the risks associated with NEC, a disease that mostly affects premature newborns, with a mortality rate ranging from 15% to 40%. The verdict signifies the opening of a legal floodgate, with hundreds of similar lawsuits pending against Mead Johnson and Abbott Laboratories Inc (NYSE: ABT ) regarding … Full story available on Benzinga.com